Brukinsa (zanubrutinib capsules and tablets) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient meets ONE of the following: has tried at least one systemic regimen OR is not a candidate for chemotherapy regimen OR Brukinsa is being used in combination with rituximab OR patient has a TP53 mutation AND medication used as induction therapy in combination with Venclexta (venetoclax tablets) and Gazyva (obinutuzumab intravenous infusion)

Approval duration

1 year